

PRESS RELEASE

Board of Fortis Healthcare approves the binding investment proposal from IHH Healthcare for an investment of INR 4,000 Crs at a per share price of INR 170

- Price of INR 170/share offers a premium of c. 20% to the current market price and c.30% to the unaffected price as on 2nd July 2018
- Proposed investment of INR 4,000 Crs offers a comprehensive equity solution addressing Fortis' liquidity requirements, obligations towards RHT acquisition and providing an exit to private equity investors of SRL
- Offers a cash exit option to 26% shareholders (on expanded share capital) through the mandatory tender offer of upto c.INR 3,300 Crs at a price of not less than INR 170 per share
- The Transaction is subject to shareholder's approval and CCI approval
- Induction of world's 2nd largest provider of integrated healthcare services (by market capitalization) and the largest healthcare provider in Asia with presence across 9 countries through 49 hospitals and more than 10,000 licensed beds

Gurugram, 13 July 2018: The Board of Directors of Fortis Healthcare Limited ("FHL") unanimously decided to recommend the binding investment proposal from IHH Healthcare Berhad ("IHH") to invest INR 4,000 Crs by way of preferential allotment at a price per share of INR 170.

Pursuant to the Board meeting held on 29th May 2018, the board of directors of FHL had initiated a fresh bidding process ("Process") to meet FHL's long term and short term objectives. 3 bidders (IHH, TPG-Manipal consortium, Hero-Burman consortium) were invited to participate in the process, and FHL had received an expression of interest from Radiant-KKR consortium. The diligence access and management interaction was offered to all the 4 bidders.

Initial bid submission date was set for June 14, 2018 which was subsequently revised and communicated to all bidders for July 3, 2018. This was subsequent to the delay in announcement of Audited accounts for financial year ending March 31, 2018.

On July 3, 2018, the Company received 2 binding proposals from IHH and TPG-Manipal consortium and the Board after considering the merits of both the bids and taking into account the recommendation of its Financial Advisors (Standard Chartered Bank and Arpwood Capital) and considering the legal advice from Legal Advisors (Luthra & Luthra Law Offices and Cyril Amarchand Mangaldas), is approving IHH's offer. The Board evaluated the bids received across various parameters including:

- Commercial terms such as valuation, quantum of investment and schedule thereof
- Plans to address FHL's liquidity requirements, including funding for RHT acquisition and for providing exit to private equity investors of SRL
- Bidder's vision and value proposition for the Company and
- Deal certainty including simplicity of transaction structure, timelines, regulatory approvals required and financing arrangement

In terms of next steps, the Company will call for a shareholder's meeting at the earliest and look forward to shareholder's approval.

The transaction is expected to be completed within 7 business days of receipt of shareholder's and CCI's approval which will be obtained concurrently with shareholder's approval and can take approximately 60-75 days.

Salient Features of the Bids:

1) IHH Healthcare:

- a. Infusion of INR 4,000 Crs through subscription to the Preferential Allotment at a price of INR 170 per share
- b. Mandatory Open Offer to the public shareholders of Fortis as per the SAST Regulations at price which is higher of INR 170 per share or price determined under Regulation 8 of SAST Regulations for 26% of the outstanding shares post issuance
- c. Mandatory Open Offer for public shareholders of Fortis Malar Hospitals Limited at a price as determined under Regulation 8 of the SAST Regulations
- d. Proposal provides for refinance of debt to the extent of INR 2,500 Crs
- e. Funds infused to be used towards completion of acquisition of assets of RHT, SRL private equity minority shareholders and short term liquidity needs

2) TPG – Manipal Consortium

- a. Infusion of INR 2,100 Crs through subscription to the Preferential Allotment at a price of INR 160 per share
- b. Proposed acquisition of stake held by private equity investors in SRL by MHEPL for a consideration of INR 1,134 Crs
- c. Acquisition of assets of RHT partially by utilizing proceeds of preferential allotment and partially through debt financing
- d. Merger of Manipal Hospitals (“MHEPL”) with FHL at a valuation attributable to MHEPL of INR 6,070 Crs and valuation of FHL basis the price per share of INR 160
- e. A rights issue / QIP post the merger to repay the bridge funding raised to complete acquisition of assets of RHT

Rationale for Approval:

Considering all key evaluation parameters, the Board approved IHH offer for consideration of FHL shareholders:

- a. Significant primary funds infusion at highest available bid price (Rs 170/share); sufficient funds commitment for future requirements
 - c. 20% premium to current market price, c.30% premium to unaffected price (2nd July 2018) and close to 52 wk high
- b. Offers significant deal certainty given a simpler transaction structure and requirement for fewer approvals and a shorter timeframe
- c. Exit opportunity for shareholders given the open offer, in case they desire
- d. Offers potential to achieve scale driven synergies on operational and financing front
- e. Integrates Fortis into a large global healthcare platform with potential synergies

Post completion of transaction the shareholding the investor can vary between c.31% to c.57% depending on the level of subscription in the mandatory tender offer from a range of 0% to 26%.



Ravi Rajagopal, Chairman, Board of Directors said “After a period of detailed consideration and evaluation, the Board of Directors is delighted to announce their approval of the IHH binding proposal. The IHH proposal offers a more strategically and financially compelling proposition along with simplicity and certainty. The process was relaunched on 29th May 2018 and has been conducted in a fair, time-bound and transparent manner. The release of the Audited FY 2018 financial statements was a key milestone in underpinning the overall success of the transaction. As part of the process, we look forward to continuing the dialogue with our shareholders ahead of the EGM to approve the transaction.”

Bhavdeep Singh, CEO, Fortis Healthcare Limited said “The proposed partnership with IHH presents exciting opportunities for Fortis while also delivering a number of synergistic avenues for the business. There is no doubt that the last twelve months have been challenging for us, however, I am confident we can collectively re-energize the entire organization. In addition to exchanging best practices and driving topline growth, we look forward to focusing back on our core business of providing world class healthcare services across India. I would like to also take this opportunity to thank all our employees, especially clinicians and nurses, for their continued commitment and support.”

For further details please contact:

Ajey Maharaj

Corporate Communication

+91-9871798573

Fortis Healthcare Limited

Anurag Kalra / Gaurav Chugh

Investor Relations

+91-9810109253 / 9958588900

Fortis Healthcare Limited

Ravi Gothwal

Investor Relations

+91-2261695988

Churchgate Partners

About Fortis Healthcare Limited

Fortis Healthcare Limited (FHL) is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 45 healthcare facilities (including projects under development), approximately 10,000 potential beds and over 368 diagnostics centres.

About IHH Healthcare Berhad

IHH Healthcare is the world’s second largest healthcare group by market capitalisation. IHH operates more than 10,000 licensed beds across 49 hospitals in 9 countries worldwide, offering the full spectrum of integrated healthcare services from clinics to hospitals to quaternary care and a wide range of ancillary services including medical education.

In Singapore, Parkway Pantai is the largest private healthcare operator with four JCI-accredited, multi-specialty tertiary hospitals - Mount Elizabeth Hospital, Mount Elizabeth Novena Hospital, Gleneagles Hospital and



Parkway East Hospital. It also owns ParkwayShenton, a large network of primary healthcare clinics and services, ParkwayHealth Radiology, ParkwayHealth Laboratory and Parkway College.

In Malaysia, Parkway Pantai is the second largest private healthcare provider operating ten Pantai Hospitals, four Gleneagles Hospitals and ancillary healthcare services including Pantai Integrated Rehab and Pantai Premier Pathology.

India is its third home market with a network of 7 hospitals and 3 medical centres in the key cities of Chennai, Bangalore, Hyderabad, Kolkata and Mumbai.

Parkway Pantai also has more than 20 patient assistance centres across the globe, providing patients with seamless patient care and a one-stop referral source to its hospitals and services.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.